Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 359

1.

The prevalence and prognostic value of BRAF mutation in thyroid cancer.

Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A.

Ann Surg. 2007 Sep;246(3):466-70; discussion 470-1.

2.

The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.

Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK.

Clin Endocrinol (Oxf). 2006 Sep;65(3):364-8.

PMID:
16918957
3.

BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.

Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, Park SY, Jung KC, Koo do H, Youn YK.

World J Surg. 2012 Feb;36(2):310-7. doi: 10.1007/s00268-011-1383-1.

PMID:
22190222
4.

Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.

Howell GM, Carty SE, Armstrong MJ, Lebeau SO, Hodak SP, Coyne C, Stang MT, McCoy KL, Nikiforova MN, Nikiforov YE, Yip L.

Ann Surg Oncol. 2011 Dec;18(13):3566-71. doi: 10.1245/s10434-011-1781-5. Epub 2011 May 19.

PMID:
21594703
5.

Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness.

Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Máximo V, Botelho T, Moreira S, Meireles AM, Magalhães J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simões M.

Virchows Arch. 2005 Jun;446(6):589-95. Epub 2005 May 19.

PMID:
15902486
6.

Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma.

Wang W, Zhao W, Wang H, Teng X, Wang H, Chen X, Li Z, Yu X, Fahey TJ 3rd, Teng L.

Ann Surg Oncol. 2012 Jan;19(1):31-6. doi: 10.1245/s10434-011-2096-2. Epub 2011 Oct 27.

PMID:
22033631
7.

Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?

Nam JK, Jung CK, Song BJ, Lim DJ, Chae BJ, Lee NS, Park WC, Kim JS, Jung SS, Bae JS.

Am J Surg. 2012 Apr;203(4):436-41. doi: 10.1016/j.amjsurg.2011.02.013. Epub 2011 Jul 30.

PMID:
21803329
8.

The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.

Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK.

Clin Endocrinol (Oxf). 2005 Nov;63(5):588-93.

PMID:
16268813
9.

BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients.

Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A.

Endocr J. 2009;56(1):89-97. Epub 2008 Oct 8.

10.

BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation.

Virk RK, Van Dyke AL, Finkelstein A, Prasad A, Gibson J, Hui P, Theoharis CG, Carling T, Roman SA, Sosa JA, Udelsman R, Prasad ML.

Mod Pathol. 2013 Jan;26(1):62-70. doi: 10.1038/modpathol.2012.152. Epub 2012 Aug 24.

11.

BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.

Kurtulmus N, Duren M, Ince U, Cengiz Yakicier M, Peker O, Aydın O, Altiok E, Giray S, Azizlerli H.

Endocrine. 2012 Oct;42(2):404-10. Epub 2012 Mar 17.

PMID:
22426956
12.

BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma.

Ahn D, Park JS, Sohn JH, Kim JH, Park SK, Seo AN, Park JY.

Auris Nasus Larynx. 2012 Apr;39(2):198-203. doi: 10.1016/j.anl.2011.07.011. Epub 2011 Aug 20.

PMID:
21862261
13.

BRAF(V600E) mutation and the biology of papillary thyroid cancer.

Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R.

Endocr Relat Cancer. 2008 Mar;15(1):191-205. doi: 10.1677/ERC-07-0212.

14.

Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant.

Smith RA, Salajegheh A, Weinstein S, Nassiri M, Lam AK.

Hum Pathol. 2011 Apr;42(4):500-6. doi: 10.1016/j.humpath.2009.09.023. Epub 2010 Dec 16.

PMID:
21167555
15.
16.

Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.

Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, Zhang Y, Cheng W, Zhao W.

Ann Surg Oncol. 2009 Feb;16(2):240-5. doi: 10.1245/s10434-008-0233-3. Epub 2008 Nov 26.

PMID:
19034577
17.

BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.

Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.

Clin Endocrinol (Oxf). 2008 Apr;68(4):618-34. Epub 2007 Dec 5.

PMID:
18070147
18.

The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome.

Russo M, Malandrino P, Nicolosi ML, Manusia M, Marturano I, Trovato MA, Pellegriti G, Frasca F, Vigneri R.

Thyroid. 2014 Aug;24(8):1267-74. doi: 10.1089/thy.2013.0675. Epub 2014 Jun 11.

PMID:
24787545
19.

Multiple genetic alterations in papillary thyroid cancer are associated with younger age at presentation.

Moses W, Weng J, Khanafshar E, Duh QY, Clark OH, Kebebew E.

J Surg Res. 2010 May 15;160(2):179-83. doi: 10.1016/j.jss.2009.05.031. Epub 2009 Jun 17.

PMID:
19765726
20.

The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors.

Choi SY, Park H, Kang MK, Lee DK, Lee KD, Lee HS, Kim SW, Lee EN, Hong JC.

World J Surg Oncol. 2013 Nov 14;11:291. doi: 10.1186/1477-7819-11-291.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk